article thumbnail

Vanda's jet-lag approval hopes for Hetlioz quashed with FDA hearing rejection

Fierce Pharma

Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. regulator, the FDA has crushed Vanda’s bid.

FDA 290
article thumbnail

Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejection

Fierce Pharma

Dating to a 2019 clinical hold of a phase 3 trial, getting its gene therapy ra | Dating to a 2019 clinical hold, getting its gene therapy pz-cel across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wait continues as the FDA has rejected the treatment due to CMC issues.

FDA 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Fierce Pharma

Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.

Biopharma 363
article thumbnail

Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years

Fierce Pharma

After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.

289
289
article thumbnail

Forrester Research Report: How Sales and Marketing Intelligence Drive Improved Business Outcomes

In 2019, DiscoverOrg commissioned Forrester Consulting to evaluate sales and marketing intelligence practices in the B2B space. Fact: Only 8% of sales and marketing professionals say their data is between 91% - 100% accurate. The primary takeaway? Forrester found “only 1.2%

article thumbnail

HHS: Younger Adults, Latino Individuals Showed Gains in Coverage From 2019 to 2021

MedCity News

in 2019, according to a recent report from HHS. The uninsured rate declined to 10.5% in 2021 from 11.1% Some of the largest gains in coverage were among demographic groups that historically have had higher uninsured rates, such as younger adults, Latino individuals, American Indian/Alaska Natives and non-English speaking adults.

Insurance 117
article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In 2019, nearly 14 of every 100 U.S.

Medicine 271
article thumbnail

The 2019 Technographic Data Report for B2B Sales Organizations

In this report, ZoomInfo substantiates the assertion that technographic data is a vital resource for sales teams. In fact, the majority of respondents agree—with 72.3% reporting that technographic data is either somewhat important or very important to their organization.